Lilly Ventures
Lilly Ventures is an Indiana-based venture capital firm that provides investment to companies in the life sciences sector.
Business Model:
Revenue: $43.1M
Employees: 51-200
Rankings
Detailed Lilly Ventures Information
Geographic Data
Address: 115 W Washington St
City: Indianapolis
State: IN
Zip: 46204
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Its primary goal is to facilitate the success of companies in its areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under management and focuses on three major areas of interest. It partner actively with the management teams of its portfolio companies to realize the potential of their technologies.
Contact Phone:
+13174290140
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2005 | GlobeImmune | Series B | 34.3M |
| 2/2014 | Aeglea BioTherapeutics | Series A | 0 |
| 3/2012 | Receptos | Venture Round | 30M |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 11/2018 | Kymera Therapeutics | Series B | 65M |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 1/2017 | Cavion | Series A | 0 |
| 6/2020 | Evox Therapeutics | Convertible Note | 10M |
| 6/2007 | Serenex | Series D | 0 |
| 10/2005 | Serenex | Series C | 30M |
| 9/2002 | Serenex | Series B | 15M |
| 11/2010 | Sutro Biopharma | Series C | 36.5M |
| 5/2005 | Bayhill Therapeutics | Series B | 35.4M |
| 11/2010 | Cerulean Pharma | Series C | 24M |
| 1/2015 | Symic Biomedical | Series A | 15M |
| 1/2015 | Surface Oncology | Series A | 35M |
| 2/2015 | Lysosomal Therapeutics | Series A | 20M |
| 6/2014 | Numerate | Series C | 8.2M |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 5/2014 | Lysosomal Therapeutics | Seed Round | 4.8M |
| 6/2009 | Aileron Therapeutics | Series D | 40M |
| 1/2012 | Coherus Biosciences | Series B | 0 |
| 6/2003 | Nanostream Inc. | Series C | 22M |
| 3/2008 | Hydra Biosciences | Series C | 34M |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 6/2018 | Nimbus Therapeutics | Series B | 65M |
| 10/2014 | Aileron Therapeutics | Series E | 33M |
| 12/2009 | FORMA Therapeutics | Series B | 3M |
| 1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
| 3/2013 | Receptos | Series B | 30M |
| 1/2005 | Remon Medical Technologies | Series C | 0 |
| 7/2015 | Protagonist Therapeutics | Series C | 0 |
| 1/2009 | Hydra Biosciences | Series D | 22M |
| 5/2009 | Avid Radiopharmaceuticals | Series D | 0 |
| 1/2004 | Hydra Biosciences | Series B | 0 |
| 3/2015 | Nimbus Therapeutics | Series B | 43M |
| 4/2006 | MedManage Systems | Series D | 10.8M |
| 4/2006 | Bayhill Therapeutics | Venture Round | 15.8M |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 12/2012 | Cerulean Pharma | Private Equity Round | 13M |
| 9/2006 | Protagonist Therapeutics | Series A | 9M |
| 8/2007 | MedManage Systems | Series E | 5M |
| 1/2007 | Standard BioTools | Series E | 0 |
| 12/2015 | Symic Biomedical | Series A | 0 |
| 9/2012 | FORMA Therapeutics | Series C | 10M |
| 1/2006 | Avid Radiopharmaceuticals | Series A | 0 |
| 12/2011 | Cerulean Pharma | Series D | 15M |
| 4/2004 | MedManage Systems | Series C | 6M |
| 12/2009 | FORMA Therapeutics | Series B | 25.5M |
| 1/2007 | Cylene Pharmaceuticals | Series C | 44M |
| 1/2013 | Aileron Therapeutics | Series D | 12M |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 9/2010 | Cylene Pharmaceuticals | Series D | 12M |
| 11/2013 | Aileron Therapeutics | Series E | 30M |
| 10/2014 | Viamet Pharma | Series D | 60M |
| 10/2017 | Kymera Therapeutics | Series A | 30M |
| 11/2002 | NexCura | Series C | 4M |
| 6/2011 | Nimbus Therapeutics | Series A | 24M |
| 7/2009 | Viamet Pharmaceuticals | Series B | 25M |
| 9/2004 | Remon Medical Technologies | Series C | 16M |
| 11/2009 | Receptos | Series A | 25M |
| 2/2006 | InnoCentive | Series A | 9M |
| 4/2010 | Viracta Therapeutics | Series B | 12M |
| 11/2007 | Viracta Therapeutics | Series A | 20M |
| 5/2007 | Avid Radiopharmaceuticals | Series C | 0 |
| 6/2013 | Protagonist Therapeutics | Series B | 0 |
| 3/2012 | Viracta Therapeutics | Series B | 0 |
| 7/2018 | Sutro Biopharma | Series E | 0 |
| 5/2012 | Sutro Biopharma | Series C | 16.5M |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 6/2020 | Evox Therapeutics | Convertible Note | 0 |
| 11/2018 | Kymera Therapeutics | Series B | 0 |
| 7/2018 | Sutro Biopharma | Series E | 0 |
| 6/2018 | Nimbus Therapeutics | Series C | 0 |
| 10/2017 | Kymera Therapeutics | Series A | 0 |
| 1/2017 | Cavion | Series A | 0 |
| 12/2015 | Symic Biomedical | Series A | 0 |
| 7/2015 | Protagonist Therapeutics | Series C | 0 |
| 3/2015 | Aeglea BioTherapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
